All posts by: Michael Zand

About Michael Zand

NY Times’ Carl Zimmer: CRISPR gene editing vital but offers ethical challenges – Genetic Literacy Project

Continue reading

2017-07-10 NEWS

Genetic Literacy Project

NY Times’ Carl Zimmer: CRISPR gene editing vital but offers ethical challenges
Genetic Literacy Project
[Editor’s Note: Carl Zimmer is a columnist at the New York Times, where his column “Matter” appears each week. He has written books, articles, and essays about the frontiers of biology and how scientists are making efforts to expand our understanding

Continue reading

2017-07-10 NEWS

Broad Institute of MIT and Harvard Joins Discussions to Create Worldwide CRISPR-Cas9 Licensing Pool
SYS-CON Media (press release)
CAMBRIDGE, Mass., July 10, 2017 /PRNewswire/ — Seeking new opportunities to make CRISPR genome editing technology widely available, the Broad Institute of MIT and Harvard has joined discussions to create a non-exclusive CRISPR-Cas9 joint …
The Broad Institute of MIT and Harvard Among Those Participating in MPEG LA’s CRISPR-Cas9 Joint Licensing …Digital Journal (press release)

all 2 news articles »

Continue reading

2017-07-10 NEWS

BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
StreetInsider.com
The clinical study collaboration between BioLineRx and Genentech, a member of the Roche Group, is part of MORPHEUS, Roche’s Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to assess the efficacy …

and more »